OR WAIT null SECS
© 2023 MJH Life Sciences and BioPharm International. All rights reserved.
© 2023 MJH Life Sciences™ and BioPharm International. All rights reserved.
October 10, 2022
Cytiva’s acquisition of CEVEC Pharmaceuticals strengthens the company’s cell line development and biomanufacturing capabilities.
July 02, 2022
Industry adoption of plant-made biologics remains slow, but plant-based technology gains an advantage by mainstream exposure.
March 02, 2022
The use of bioengineering offers practical tools for the evolution of host cells.
July 22, 2021
Catalent Biologics has launched its new cell line expression technology, GPEx Lightning, which aims to shorten drug substance development timelines by up to three months.
April 06, 2021
The company has introduced Opto Assure, a series of assays that provide yield and product quality data at an earlier stage in cell-line development.
January 02, 2021
Cell-culture optimization may see benefits from a synthetic biology-based approach that improves product titer, quality, and time.
October 29, 2020
Samsung Biologics has adopted Solentim’s cell seeding and cell metric platforms at its new R&D center in San Francisco, CA.
Mogrify’s new technology platform, EpiMOGRIFY, can predict cellular switches important for determining cell identity, cell maintenance, directed differentiation, and cell conversion.
October 02, 2020
An innovation such as synthetic biology can develop a consistently stable starting cell line for cell therapy source material.
September 03, 2020
This article will explore the traditional path from the laboratory to the clinic and how the fixed-bed technology provides an alternative solution to meet commercial demands.